Latest News
-
Monday - December 7, 2020
Not intended for U.S. and UK Media
Bayer and Atara Biotherapeutics enter strategic collaboration for next generation, mesothelin-targeted CAR-T cell therapies for solid tumors
Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy / Bayer to enter CAR-T cell therapy space and expand oncology development pipeline with groundbreaking technology / Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy / Partnership will focus on the next generation, off-the-shelf T-cell immunotherapy ATA3271 for treatment of high mesothelin-expressing tumors / Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low double-digit percentage of net sales » more
-
Wednesday - December 2, 2020
Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation
Cell and Gene Therapy Platform (C& GT) to drive groundbreaking science delivering breakthrough innovative treatments for patients / New Platform will steer strategically and orchestrate all activities along the value chain / Bayer’s C& GT pipeline already comprises five advanced assets and over fifteen preclinical candidates / Acquisition of Asklepios Biopharmaceutical successfully closed on December 1, 2020 / Wolfram Carius appointed Head of Bayer’s new C& GT Platform » more
-
Tuesday - December 1, 2020
Not intended for U.S. and UK Media
Bayer and Blackford Analysis to Collaborate on Integration of AI Solutions in Medical Imaging Workflow
Partners will establish new platform delivering centralized access to digital and AI applications throughout medical imaging workflow / Bayer to expand its AI capabilities and accelerates innovation in medical imaging together with health-technology partners / AI in medical imaging increases efficiency and reduces diagnostic errors with the potential to positively impact disease management and patient outcomes » more
-
Tuesday - December 1, 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion » more
-
Monday - November 30, 2020
Bayer introduces Fludora® Co-Max to combat resistant mosquitoes and control vector-borne diseases worldwide
Innovative combination space spray solution demonstrates improved efficacy in controlling Aedes mosquitoes - vectors of arboviral diseases » more
-
Wednesday - November 18, 2020
BlockApps Launches Agribusiness Blockchain Network ‘TraceHarvest’ Following Success with Bayer
BlockApps’ Ethereum-based TraceHarvest Network enhances food quality, safety and sustainability by bringing supply chain efficiencies, transparency, compliance and stewardship to agricultural products » more
-
Wednesday - November 18, 2020
Bayer initiates new G4A Digital Health Partnerships Program
Focus on fostering development of integrated healthcare solutions in fields of cardiometabolic and renal diseases, oncology, and women’s health / Germany’s Federal Minister of Health Jens Spahn to give keynote at the virtual digital health forum “G4A Agents of Change” at 5pm CET/11am EST today » more
-
Tuesday - November 17, 2020
Bayer Acquires Majority Stake in Care/of
Deal deepens Bayer’s capabilities in the personalized healthcare and nutritionals space » more
-
Tuesday - November 17, 2020
Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease
In the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that specifically addresses MR overactivation, a key driver of disease progression » more
-
Friday - November 13, 2020
Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children
Pediatric patients currently have limited therapeutic options and until now, there have been no approved oral treatments because of the absence of appropriate clinical trials / After approval, rivaroxaban would be the only oral Factor Xa Inhibitor authorized to treat VTE and prevent VTE recurrence in children / An oral suspension of rivaroxaban that does not require injections or regular monitoring has been developed to facilitate pediatric administration / CHMP opinion is based on the largest pediatric thromboembolism program completed to date, including the phase III EINSTEIN-Jr. study » more
-
Thursday - November 12, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases / Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient access to cell and gene therapies » more
-
Monday - November 9, 2020
Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes
Regulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicine » more
-
Tuesday - November 3, 2020
Bayer:
Challenging third quarter – Group outlook confirmed
Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals business recovering – higher earnings but slightly lower sales / Strong performance at Consumer Health / Net loss of 2.744 billion euros – impairment charges at Crop Science, proceeds from divestment of Animal Health / Core earnings per share decline by 30.2 percent to 0.81 euros / Free cash flow falls by 2.1 percent to 1.237 billion euros » more
-
Wednesday - October 28, 2020
Bayer launches first Global Creative Council: raising the bar for the Consumer Health Industry
Senior Marketing Leaders from top creative agencies and world-renowned brands volunteering to work with Bayer to enhance creativity and inspire consumers to take better care of their health » more
-
Tuesday - October 27, 2020
The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer’s low-volatility dicamba product
The new registration follows launch announcement for XtendFlex® soybeans and enables full potential of industry-leading Roundup Ready® Xtend Crop System » more
-
Tuesday - October 27, 2020
Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development » more
-
Tuesday - October 27, 2020
60% of parents & parents-to-be do not realise that nutrition directly impacts a baby's growth and development during pregnancy
Bayer launches Mission 1000+ campaign to empower parents with knowledge about the role of nutrition in their baby’s development » more
-
Monday - October 26, 2020
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, as well as out-licensed clinical candidates for hemophilia and Duchenne muscular dystrophy / Acquisition secures additionally revenue generating Contract Development and Manufacturing Business based on highly efficient Pro10™ Cell line / AskBio to operate autonomously and on an arms-length basis / Purchase price of USD 2 billion upfront and up to USD 2 billion in success-based milestone payments » more
-
Monday - October 26, 2020
Not intended for U.S. and UK Media
Rivaroxaban application submitted to U.S. FDA for new indication in patients after lower-extremity revascularization due to symptomatic PAD
FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD » more
-
Friday - October 23, 2020
Not intended for U.S. and UK Media
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patients
The companion diagnostic (CDx) approval is part of the global collaboration between Bayer and Foundation Medicine, Inc. for the development and commercialization of next-generation sequencing (NGS)-based companion diagnostics in oncology / Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, such as available biomarker driven therapies / FoundationOne®CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the three NTRK gene fusions (NTRK1, NTRK2 and NTRK3), to inform treatment decisions(1) / Vitrakvi™ (larotrectinib) is the first and only TRK-specific inhibitor approved in the U.S. for adult and pediatric patients with TRK fusion cancer across all solid tumors and is under review in other markets around the world » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, April 27, 2021
Annual Stockholders' Meeting 2021
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV